Journal of the American Academy of Dermatology
Volume 62, Issue 3 , Pages 427-436 , March 2010

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

  • Robert Bissonnette, MD

      Affiliations

    • Innovaderm Research, Inc, Montreal, Quebec, Canada
    • ,
  • Kim Papp, MD

      Affiliations

    • Probity Medical Research, Waterloo, Ontario, Canada
    • ,
  • Catherine Maari, MD

      Affiliations

    • Innovaderm Research, Inc, Laval, Quebec, Canada
    • ,
  • Yihong Yao, PhD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • ,
  • Gabriel Robbie, PhD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • ,
  • Wendy I. White, PhD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • ,
  • Chenxiong Le, PhD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • ,
  • Barbara White, MD

      Affiliations

    • MedImmune, LLC, Gaithersburg, Maryland
    • Corresponding Author InformationReprint requests: Barbara White, MD, MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878.

,Accepted 14 May 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by MedImmune, LLC.

 Disclosure: Drs Yao, Robbie, White, Le, and White are employees of MedImmune. Dr Bissonnette received research funding from MedImmune for this study; has received research funding, is a consultant, and/or has received honoraria from MedImmune, LLC, Amgen, Inc, Wyeth, Inc, Centocor/Schering-Plough, Ortho-Biotech, Abbott Laboratories, Astellas, and EMD Serono, Inc. Dr Papp received research funding from MedImmune for this study; has received research funding, is a consultant, Speaker Bureau, and/or investigator for MedImmune, Abbott Laboratories, Amgen, Inc, Celgene Corporation, Merck-Serono, Schering-Plough, and Wyeth, Inc. Dr Maari received research funding from MedImmune for this study; is a consultant and/or has received honoraria from Amgen, Inc, Wyeth, Inc, Centocor/Schering-Plough, Ortho-Biotech, Abbott Laboratories, Astellas, and Galderma.

PII: S0190-9622(09)00686-0

doi: 10.1016/j.jaad.2009.05.042

Journal of the American Academy of Dermatology
Volume 62, Issue 3 , Pages 427-436 , March 2010

Article Tools

* Image Usage & Resolution